Celularity, Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest

Celularity, Inc. (NASDAQ:CELU) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 1,897,722 shares, a growth of 370.2% from the August 15th total of 403,568 shares. Based on an average daily volume of 21,797,628 shares, the days-to-cover ratio is currently 0.1 days. Currently, 7.9% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Celularity has a consensus rating of “Sell”.

Celularity Stock Down 1.4%

Shares of CELU traded down $0.02 during midday trading on Friday, hitting $1.42. The company had a trading volume of 76,866 shares, compared to its average volume of 1,524,144. Celularity has a 52 week low of $0.56 and a 52 week high of $2.55. The company’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.01. The stock has a market cap of $40.96 million, a price-to-earnings ratio of -0.42 and a beta of 0.79.

Hedge Funds Weigh In On Celularity

Several institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Celularity in the fourth quarter valued at $33,000. Acadian Asset Management LLC bought a new stake in Celularity during the 1st quarter valued at $34,000. Jane Street Group LLC acquired a new position in shares of Celularity during the fourth quarter valued at $46,000. Bank of America Corp DE grew its position in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after acquiring an additional 20,876 shares during the period. 19.02% of the stock is owned by institutional investors.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.